Patients
Trials
Expanded Access
Pipeline
Zanidatamab
ZW49
Preclinical & Advanced Discovery
Partnerships
Publications
Partners
Technology
Azymetric™
ZymeLink™
EFECT™
ProTECT™
Science
Careers
Apply
Perks & Benefits
Corporate Gallery
About
Leadership
Board of Directors
News
Investors & Media
Zymeworks Announces Second Janssen Bispecific Antibody To Begin Clinical Development Utilizing Azymetric™ And EFECT™ Therapeutic Platforms
Dec 01, 2021
Back